Diabetes Complications: Heart, Kidney, Eye, Nerve and Foot — How to Protect Yourself

How diabetes affects the heart, kidneys, eyes, nerves and feet, the screening schedule that catches problems early, and how integrated care protects you.

High blood sugar over years can affect the heart, kidneys, eyes, nerves and feet — often silently. The good news is that regular checks and early treatment prevent most serious complications. This guide explains each complication, the warning signs and the screening schedule that protects you.

One diabetes diagnosis, often several layers.

Diabetes damages both metabolism and vasculature, and rarely travels alone. Here are the six combinations we see most often — and the specific sequenced approach for each.

🌧

Diabetes + Depression

~30% comorbidity

Depression is twice as common in adults with diabetes as in the general population, and it predicts worse HbA1c, lower medication adherence, and higher complication rates. The relationship is bidirectional — chronic disease drives depression; depression worsens self-care and biological markers (Anderson RJ 2001 meta-analysis).

Integrated care plan: PHQ-9 + PAID-5 at baseline · If depression moderate-severe (PHQ-9 ≥15), psychiatry referral · SSRI (sertraline preferred — CV-safe) · Diabetes-focused CBT for concurrent distress · CGM to give sense of control back · Watch for hypoglycemia-mimicking-depression pattern · Quarterly PHQ-9 re-check

T2DM + Established ASCVD (Heart Disease)

~35% prevalence

Adults with T2DM have 2-4× higher CV mortality than those without diabetes. ADA 2025 now recommends SGLT2i and/or GLP-1RA as second-line after metformin whenever ASCVD is present, regardless of HbA1c — because these classes reduce CV death independent of glucose lowering (EMPA-REG, LEADER, SELECT).

Integrated care plan: Cardiology co-referral · SGLT2i (empagliflozin) + GLP-1RA (semaglutide) combination often optimal · High-intensity statin (atorvastatin 40-80 mg / rosuvastatin 20-40 mg) targeting LDL <55 mg/dL · ACEi/ARB · Aspirin only for secondary prevention · BP target <130/80 · Annual ECG, echo if symptoms

💧

Diabetes + Chronic Kidney Disease (CKD)

~40% lifetime prevalence

Diabetic nephropathy is the leading cause of end-stage renal disease worldwide. Detected early by urine albumin (microalbuminuria) or falling eGFR. SGLT2 inhibitors have transformed CKD management (DAPA-CKD, EMPA-KIDNEY, CREDENCE) — slowing decline and reducing dialysis need. GLP-1RA also renoprotective (FLOW 2024).

Integrated care plan: Annual urine ACR + eGFR · Nephrology referral if eGFR <30 or rapid decline · SGLT2i (dapagliflozin, empagliflozin) if eGFR ≥20-25 · ACEi/ARB titrated to max tolerated · Metformin dose reduction below eGFR 45, stop <30 · Avoid NSAIDs · BP <130/80 (may need 3-4 agents) · Finerenone for albuminuric CKD (FIDELIO/FIGARO)

Diabetes + Diabetic Retinopathy

~30% prevalence (any grade)

All grades from mild NPDR to sight-threatening proliferative DR and diabetic macular oedema. Screening — dilated fundus exam or retinal photography — is mandatory annually for T2DM from diagnosis, T1DM from 5 years duration, and any pregnancy with pre-existing diabetes. Rapid HbA1c reduction can transiently worsen retinopathy (early worsening) — plan cautiously.

Integrated care plan: Annual dilated fundus exam or retinal photography · Ophthalmology co-management for any DR >mild NPDR · Anti-VEGF (aflibercept, ranibizumab) for macular oedema · Slow HbA1c reduction if severe DR present · Optimise BP and lipids in parallel · Pregnancy planning: dilated exam pre-conception and each trimester

🦶

Diabetes + Peripheral Neuropathy & Foot Ulcers

~40% peripheral neuropathy

Distal symmetric polyneuropathy (numbness, tingling, burning in feet) affects ~40% of adults with long-duration diabetes. Combined with peripheral arterial disease, it drives most diabetic foot ulcers — a leading cause of amputation globally. Annual foot exam with monofilament testing is mandatory per ADA guidelines.

Integrated care plan: Annual foot exam with 10g monofilament + tuning fork + pulse check · Daily patient foot self-examination · Proper footwear + off-loading if ulcer risk · Podiatry referral for callus care · Neuropathy symptom control (duloxetine, pregabalin, gabapentin) · Vibration/pinprick testing · Prompt treatment of any wound >2 wks (podiatry + wound care team)

😴

T2DM + Obstructive Sleep Apnea (OSA)

~50% prevalence in T2DM

Very common and very under-diagnosed. OSA independently worsens insulin resistance, drives dawn glucose rises, elevates BP, and increases CV risk. CPAP therapy improves HbA1c by 0.2-0.4% in patients with moderate-severe OSA. Common signs: loud snoring, witnessed apneas, morning headaches, daytime sleepiness, resistant hypertension.

Integrated care plan: STOP-BANG screening at baseline + ESS · Sleep study (home polysomnography or Level 3 test) if screening positive · CPAP titration if AHI ≥15 (or ≥5 with symptoms/comorbidities) · Weight loss (highly effective for OSA) · Positional therapy if positional OSA · Avoid alcohol + sedatives before sleep · Repeat HbA1c 3 months after CPAP started

Diabetes + another condition?

Diabetes rarely travels alone.

Diabetes damages small vessels (retina, kidney, nerves) and large vessels (heart, brain, legs). Roughly 30% of adults with diabetes have clinical depression; up to 40% have anxiety or diabetes distress; 40-50% have chronic kidney disease over their lifetime; established ASCVD is 2-4× more common than in non-diabetics. Treating diabetes in isolation while missing these comorbidities usually undertreats overall mortality risk.

~30%Diabetes + Depression

~40%Diabetes + Anxiety / Distress

~40%T2DM + Chronic Kidney Disease

~35%T2DM + Established ASCVD

~30%Diabetes + Retinopathy (any grade)

~50%T2DM + Sleep Apnea

~40%T2DM + Peripheral Neuropathy

~85%T2DM + Dyslipidemia

Prevalence figures from IDF Diabetes Atlas 2021, ICMR-INDIAB 2023, Anderson RJ meta-analysis on depression in diabetes ( Diabetes Care 2001), Foster GD et al. sleep apnea in T2DM ( Diabetes Care 2009), Gregg EW long-term complications trends ( NEJM 2014).

What comprehensive diabetes care actually looks like today.

Glucose Monitoring & CGM Interpretation

Traditional HbA1c every 3 months, self-monitoring blood glucose (SMBG), and increasingly continuous glucose monitoring (CGM). Time-in-Range (TIR >70% at 70-180 mg/dL) is the modern metric. Sensor upload allows remote AGP review with your diabetologist every 2 weeks.

Modern practice: CGM or CGM for 14 days, ambulatory glucose profile (AGP) report reviewed by video with your diabetologist to adjust meals, timing and doses.

💊

Medication Optimisation

Beyond HbA1c: right drug for your cardio-renal risk profile. Metformin first-line, then SGLT2i (heart failure, CKD) or GLP-1RA (obesity, ASCVD). ADA 2025 recommends BOTH in many T2DM+ASCVD patients. De-escalation as you improve.

Modern practice: A T2DM patient with ASCVD gets metformin + empagliflozin + semaglutide + statin + ACEi + aspirin — organ protection layered onto glucose control

🥗

Medical Nutrition Therapy

Not "eat less sugar" but structured, Indian-appropriate meal planning by a certified dietitian. Carb counting or Indian roti-sabzi portioning. Emerging role for time-restricted eating and low-carb approaches for T2DM (evidence still evolving).

Modern practice: Personalised 1400-1800 kcal Indian meal plan with 40-45% carbs, 20-25% protein, low glycemic index staples (millets, whole dals), matched to your medications and CGM data.

🏃

Structured Physical Activity

Aerobic (150 min/week moderate or 75 min vigorous), resistance training (2+ sessions/week), and reducing sedentary time (breaking up sitting every 30 min). Combined aerobic + resistance is superior to either alone for T2DM (HART-D trial).

Modern practice: 30 min brisk walk 5 days/week + 2 resistance sessions (bodyweight or bands) + stand-up-every-30-min at work. Tracked via smartphone or fitness band.

⚖️

Weight Management

≥5% weight loss meaningfully improves glucose; ≥10% opens the remission window. GLP-1 RAs (semaglutide, tirzepatide) have made 15-20% weight loss pharmacologically achievable (STEP, SURPASS trials). Bariatric/metabolic surgery remains highly effective for BMI ≥35 with T2DM.

Modern practice: For BMI ≥27 with T2DM, discuss GLP-1 or dual GIP/GLP-1 agonist (tirzepatide) alongside lifestyle. For BMI ≥35 with poor control, bariatric consult with STAMPEDE-style outcomes evaluation.

🧠

Diabetes Distress & Depression Management

Roughly 30% of people with diabetes have clinical depression; even more have diabetes-specific distress (measured by DDS-17). Untreated psychological load worsens self-care and outcomes. Standard care now includes annual PHQ-9 + DDS screening with psychology referral when flagged.

Modern practice: Annual PHQ-9 + DDS-17. If elevated, referral to CBT-trained psychologist for diabetes-specific therapy — reduces distress AND improves HbA1c in RCTs.

Cardio-Renal-Retinal-Foot Protection

Diabetes damages vessels — small (retina, kidney, nerves) and large (heart, brain, legs). ADA 2025 mandates: annual dilated eye exam, annual urine albumin, annual foot exam with monofilament, aggressive LDL <70 mg/dL if ASCVD, BP <130/80. Statin + ACEi/ARB nearly universal by age 40.

Modern practice: Annual retinography, annual urine ACR, quarterly kidney function, statin from diagnosis if age ≥40, ACEi/ARB if hypertension or microalbuminuria, aspirin only in secondary prevention.

📚

Structured Diabetes Self-Management Education (DSME)

Not just a leaflet — structured curricula like DAFNE (T1DM), DESMOND (T2DM), or X-PERT programmes teach carb counting, sick-day rules, hypoglycemia recognition, insulin dose adjustment, and psychological coping. Consistently improve HbA1c and reduce complications.

Modern practice: 4-6 group sessions with a certified diabetes educator covering carbs, hypo action plan, insulin adjustment, foot care, sick-day rules, alcohol, travel — recommended at diagnosis and refreshed annually.

Pillars mapped to your specific profile